Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jun;42(3):737-43.
doi: 10.1177/0300060513510657. Epub 2014 Apr 9.

Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer

Lei Dong  1 , Jing Li  2 , Xiao-Ping Lou  2 , Jin-Hong Miao  2 , Pei Lu  3 , Zhi-Wei Chang  3 , Zhao-Feng Han  4
Affiliations
Randomized Controlled Trial

Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer

Lei Dong et al. J Int Med Res. 2014 Jun.

Abstract

Objective: To compare the short-term efficacy and safety profile of the S-1 + irinotecan + oxaliplatin (TIROX) and docetaxel + cisplatin + flurouracil (DCF) anticancer regimens in patients with advanced gastric cancer.

Methods: Patients with recurrent or metastatic gastric cancer diagnosed by pathology were randomly divided into two groups to receive six cycles of either the TIROX regimen (21-day cycle) or the DCF regimen (21-day cycle). After six chemotherapy cycles, the short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines and adverse reactions were recorded according to National Cancer Institute Common Toxicity Criteria 2.0 standards.

Results: A total of 60 patients were enrolled in the study. The response rate (complete response + partial response) was significantly higher in the TIROX group (18/30 patients; 60.0%) compared with the DCF group (10/30 patients; 33.3%). The rates of grade III-IV leucopenia and neurotoxicity were significantly higher in the TIROX group than the DCF group.

Conclusion: The TIROX regimen was effective for the treatment of advanced gastric cancer, but it was associated with leucopenia and neurotoxicity.

Keywords: Advanced gastric cancer; DCF regimen; S-1; TIROX regimen.

PubMed Disclaimer

References

    1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354–362. - PMC - PubMed
    1. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153–156. - PubMed
    1. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005; 241: 27–39. - PMC - PubMed
    1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009; 472: 467–477. - PubMed
    1. Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers (Basel) 2013; 5: 48–63. - PMC - PubMed

Publication types

MeSH terms